The $100B Cardiovascular Arena in 2025: Revenue Rankings and Technology Showdown Among the Top Five Global Giants Dominating Atrial Fibrillation and Valve Therapies

Jan 02, 2026 06:00 CST Updated 06:00

Medtronic

Chronic Disease Medical Device and Therapy Developer

Abbott

Diagnostic and pharmaceutical product manufacturers

权威机构报告：中国509万人死于心血管疾病，与老龄化密切相关|中风|心血管|中国_新浪新闻

Introduction: The "Golden Age" of the Cardiovascular Device Track and the Giant Landscape

1.1 Global Cardiovascular Device Market: Size, Growth Logic, and Core Segments

Global Cardiovascular Devices Market Size Reaches USD 72.83 Billion in 2024, Growing by 7% Year-on-Year; Interventional Cardiology Accounts for the Largest Share, While Structural Heart Disease Leads with Fastest Growth Rate; Pulmonary Field Ablation (PFA), Transcatheter Aortic Valve Replacement (TAVR), and Leadless Pacemakers Become the "Three Key Drivers" of Growth; Aging Population and Rising Demand for Minimally Invasive Treatments Propel Continuous Market Expansion; Leading Companies Dominate Over 70% Market Share Due to Technological Barriers.

1.2 The "Pass" for the Five Giants: Revenue Thresholds and Industry Influence

This list focuses on cardiovascular business revenue for 2024-2025 as the core indicator, selecting five companies: Medtronic, Abbott, Boston Scientific, Johnson & Johnson MedTech (J&J MedTech), and Edwards Lifesciences. Their combined revenue accounts for 58% of the global market, and each company has a "leading product" in at least one core technology track (such as PFA or TAVR), driving the direction of industry technological iteration.

Medtronic: The "Dual-Engine Drive" at the Top of the Revenue Chart —— The Explosion of PFA and Global Expansion

2.1 Revenue Performance: Cardiovascular Business Revenue of 11.831 Billion Swiss Francs in 2024, Remaining the World's Largest

In the fiscal year 2024 (April 2023 - April 2024), Medtronic's cardiovascular business revenue accounted for 37% of the group's total revenue, increasing by 2.7% year-over-year. Of this, the U.S. market contributed 47.3% of the revenue (5.597 billion Swiss francs), while emerging markets became a new growth driver with a 10% year-over-year growth rate. The procurement volume of its Affera PFA system in regions such as China and India increased by over 80% year-over-year.

2.2 Technical Ace: Dual PFA Products + Leadless Pacemaker, Building a "Closed-loop for Atrial Fibrillation Treatment"

As the first company globally to launch two PFA products, its PulseSelect system complements the Sphere-9 dual-energy catheter – the former focuses on rapid atrial fibrillation treatment, while the latter adapts to complex cases through a "PFA + radiofrequency" dual-energy mode, with PFA business growth in the U.S. market exceeding 300% in 2024; the battery life of the Micra AV2/VR2 leadless pacemakers reaches 16-17 years, with remote monitoring functionality covering over 90% of implanted patients, reducing hospitalization rates by 30%.

2.3 Challenges and Responses: The Decline in the U.S. Market and Breakthroughs in Structural Heart Disease

U.S. Market Revenue Declines 3.4% Year-over-Year in 2024, Primarily Due to Pricing Pressure from Local Competitor PFA; In Response, the Company Accelerates Harmony Transcatheter Pulmonary Valve (TPV) Development, Receives CE Mark in January 2025 as the World’s First Self-Expanding TPV, Expected to Drive 15% Growth in Structural Heart Disease Business Post-U.S. Launch in 2026.

Abbott: The "Multi-Pronged" Growth Leader - Structural Heart Disease and Electrophysiology Powering Ahead

3.1 Revenue Ranking: Cardiovascular revenue in 2024 reached $11.219 billion, a year-on-year surge of 9.6%.

In 2024, Abbott's cardiovascular business accounted for 59% of the medical device segment’s revenue, with the structural heart disease business leading at a year-over-year growth rate of 15.8%. Global sales of the TriClip tricuspid valve repair device and the Amplatzer left atrial appendage closure device exceeded 120,000 cases and 80,000 cases, respectively. Revenue in the U.S. market reached $5.388 billion (structural heart disease grew by 19%), while international markets generated $5.831 billion (electrophysiology business grew by 12.6%).

3.2 Technical Highlights: The "Precision Treatment" of Volt PFA System and Navitor TAVI

The Volt PFA system, combining a basket-shaped balloon catheter with EnSite X cardiac mapping technology, improves positioning accuracy by 40% and is expected to exceed 50,000 global procedures in 2024; the Navitor TAVI system features a "largest valve + smallest delivery system" design tailored for complex aortic stenosis cases and is projected to capture 15% of the TAVR market share following its U.S. launch in 2025.

3.3 Business Features: From "Equipment Sales" to "Full-cycle Management"

Relying on the synergy of businesses in cardiac rhythm management, heart failure, and vascular care, Medtronic has launched the "Full-cycle Patient Management Solution" — which uses wearable devices to monitor patients' heart rate and blood pressure in real time after surgery, with data synchronized to the hospital system. In 2024, the readmission rate for patients participating in the solution decreased by 22%, enhancing user engagement.

Boston Scientific: The "Comeback Player" in the Electrophysiology Field – FARAPULSE PFA Ignites Growth

4.1 Revenue Soars: Cardiovascular Revenue Reaches $10.755 Billion in 2024, Up 22% Year-over-Year

In 2024, Boston Scientific's cardiovascular business growth ranked first among the five giants, driven primarily by its electrophysiology segment — global sales of the FARAPULSE PFA System reached $19.04 billion, surging 139.5% year-over-year, with a penetration rate of 35% within six months of FDA approval in the U.S., replacing 20% of cryoablation procedures; coronary intervention revenue was $28.37 billion, increasing 5.8% year-over-year, with a global market share of over 25% for drug-coated balloons.

4.2 Technical Barriers: The "Efficiency Revolution" of the FARAWAVE NAV Catheter

Launch the new generation FARAWAVE NAV PFA catheter in October 2024, reducing procedure time to 45 minutes (industry average 60 minutes) via 3D mapping technology, with a complication rate of 0.8%; supports "one-stop atrial fibrillation treatment," enabling simultaneous lesion localization, ablation, and postoperative evaluation. The goal for 2025 is to become the global leader in electrophysiology market share (currently second).

4.3 China Layout: Leveraging Centralized Procurement to Accelerate Domestic Substitution

In the 2024 China centralized procurement, the winning bid prices for its coronary stents and balloon products were 15%-20% lower than imported competitors, rapidly entering over 300 tertiary Class A hospitals. The FARAPULSE PFA system has entered China's "green channel" and is expected to be launched in 2026, targeting China's market of 2 million atrial fibrillation patients.

Johnson & Johnson MedTech (J&J MedTech): The "Steady and Deep Cultivation" of the Electrophysiology Leader

5.1 Revenue Performance: 2024 Cardiovascular Revenue Not Disclosed, Electrophysiology Business Accounts for 68%

In 2024, J&J MedTech's cardiovascular business grew by 21.4% (second only to Boston Scientific), with the core being the electrophysiology segment — the VARIPULSE PFA System received CE certification in February 2024 and FDA approval in November, utilizing "precise pulse energy modulation" technology, suitable for atrial fibrillation patients with comorbid hypertension, with over 30,000 global surgical procedures; In the Chinese market, rapid distribution was achieved through a "dealer cooperation model," with electrophysiology product sales growing by 28% year-on-year in 2024.

5.2 Technical Features: From "Single Lesion Treatment" to "Multi-Organ Coordination"

Leveraging the group's advantages in surgical and neurointerventional businesses, develop the "Cardio-Cerebral Synergistic Treatment Plan" – for patients with atrial fibrillation and stroke risk, simultaneously providing VARIPULSE PFA ablation and cerebral vascular stent implantation services. In 2024, over 10,000 combined surgeries will be completed globally, reducing the 5-year stroke incidence rate by 35% for patients.

Edwards Lifesciences: The "Single Champion" of Structural Heart Disease — The Transformation of the TAVR Leader

6.1 Revenue Positioning: Cardiovascular revenue of $54.4 billion in 2024, up 8.9% year-over-year (100% focused on cardiovascular)

After Edwards spun off its critical care business in 2024, it became a pure cardiovascular company. The TAVR business generated $20.46 billion in revenue (accounting for 37.6%), while the TMTT (transcatheter mitral/tricuspid therapies) business surged with a 75% year-over-year growth rate. Global sales of the PASCAL mitral valve repair device exceeded 50,000 cases; however, due to lower-than-expected TAVR sales, the company's annual revenue growth was below the industry average.

6.2 Technical Core: SAPIEN TAVR Platform and M&A Enhancement "Dual Pathway"

The SAPIEN TAVR series holds nearly 70% of the global market share. In 2024, the SAPIEN M3 mitral valve replacement system will be launched, designed for high-risk patients. Through $1.5 billion acquisitions of JenaValve (TAVR) and Endotronix (heart failure sensors), the company strengthens its presence in the pulmonary valve and heart failure monitoring sectors. The Cordella pulmonary artery pressure sensor received FDA approval in 2024 and is expected to generate $200 million in revenue by 2025.

6.3 Future Focus: The "Second Growth Curve" of TMTT Business

TMTT's revenue reached $156 million in 2024, with a target to exceed $340 million by 2025; the focus is on advancing the development of tricuspid valve replacement products, with FDA approval expected by 2026. Targeting the global market of 1.5 million patients with severe tricuspid regurgitation, it aims to replicate the successful path of TAVR.

Five Giants Horizontal PK: A "Three-Dimensional Comparison" of Revenue, Technology, and Potential

7.1 Revenue Ranking and Growth Rate for 2024-2025

Revenue ranking: Medtronic (11.831 billion Swiss francs) > Abbott (11.219 billion USD) > Boston Scientific (10.755 billion USD) > J&J MedTech (not disclosed, estimated 9-9.5 billion USD) > Edwards (5.44 billion USD); Growth rate ranking: Boston Scientific (22%) > J&J MedTech (21.4%) > Abbott (9.6%) > Edwards (8.9%) > Medtronic (2.7%), with electrophysiology business becoming the key growth driver.

7.2 Differences in Technical Track Layout: The Divide Between "Specialists" and "Generalists"

Medtronic and Abbott are "all-round players," covering multiple fields such as PFA, TAVR, and leadless pacemakers; Boston Scientific and J&J MedTech focus on "single-point breakthroughs in electrophysiology"; Edwards is a "specialist in structural heart disease." In terms of technical barriers, Boston Scientific and Medtronic lead in the PFA field, Edwards and Medtronic dominate in the TAVR field, and Medtronic and Abbott have the advantage in the leadless pacemaker field.

Future Outlook: Three Major Trends and Giant Challenges in the Cardiovascular Device Track

8.1 Technology Iteration: From "Single Technology Breakthrough" to "Multi-Technology Integration"

It is expected that from 2025 to 2030, integrated technologies such as "PFA+AI Navigation" and "TAVR+Remote Monitoring" will become mainstream. For example, Medtronic plans to add AI lesion recognition functionality to its Sphere-9 catheter, further improving surgical precision by 20%. Data interoperability between leadless pacemakers and wearable devices will cover 60% of patients, achieving full digitalization of the "implantation-monitoring-follow-up" process.

8.2 Market Competition: Competition in Emerging Markets and Pressure from Domestic Substitutes

Emerging Markets like China and India Show 12%-15% Annual Growth in Cardiovascular Device Demand; Top Five Companies Accelerate Local Production (e.g., Abbott Building PFA Catheter Factory in Shanghai); Meanwhile, Domestic Companies (e.g., Lepu Medical) Surpass 50% Market Share in Coronary Stents and Balloons, Poised to Breakthrough into PFA and TAVR Segments, Squeezing Import Product Shares.

8.3 Policy Impact: The "Double-Edged Sword" of Centralized Procurement and Medical Insurance Coverage

Summary: China’s centralized procurement has extended to the valve field (with TAVR included for the first time in 2024). The winning bid prices of Edwards and Medtronic products dropped by 30%-40%, but sales volume increased by 50%. The U.S. CMS plans to include renal denervation in Medicare by October 2025, benefiting Medtronic's related product sales. Policies will force giants to balance "low-price wins" with "profit margins," promoting cost control and technological innovation.